Overview: Total Protein CSF TestIntroduction: The Total Protein CSF Test measures total protein in cerebrospinal fluid to diagnose neurological disorders, causing headaches. Aligned with 2023 AAN guidelines, it uses biochemical methods for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in clinical pathology for patients with suspected meningitis or multiple sclerosis.
Other Names: Protein CSF Assay, CSF Protein Test.
FDA Status: Laboratory-developed test (LDT), meeting clinical pathology standards for diagnostic accuracy.
Historical Milestone: CSF protein testing began in the 1950s with neurological research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures total protein in CSF to diagnose neurological disorders, guides treatment, and evaluates patients with headaches.
Test Parameters: 1. Total Protein Level
Pretest Condition: No fasting required. Collect CSF. Report history of headaches or neurological symptoms.
Specimen: CSF (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document headaches, neurological symptoms, or history of meningitis/multiple sclerosis. Include current medications, especially steroids.
Consent: Written consent required, detailing the tests purpose, neurological disorder implications, and risks of lumbar puncture.
Procedural Considerations: Uses colorimetric or turbidimetric methods to measure CSF protein levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for neurological diagnosis.
Factors Affecting Result Accuracy: Improper sample collection or blood contamination can affect results. Recent trauma may elevate protein levels.
Clinical Significance: Elevated CSF protein confirms neurological disorders, guiding antibiotic or immunosuppressive therapy. Normal levels may require MRI or oligoclonal band testing.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: CSF cell count, MRI, or oligoclonal bands to confirm neurological disorder diagnosis.
Test Limitations: Non-specific for certain neurological conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Meningitis Guidelines, 2023; Neurology, Deisenhammer F, 2022.
